Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Point-of-care testing and home testing: Pragmatic Considerations for Widespread Incorporation of Stool Tests, Serum Tests, and Intestinal Ultrasound

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Loss of sucrase-isomaltase function increases acetate levels and improves metabolic health in Greenlandic cohorts

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Neutralizing Antibodies Against Hepatitis C Virus and Their Role in Vaccine Immunity

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  3. Validation and Update of the Lemann Index to Measure Cumulative Structural Bowel Damage in Crohn's Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Challenges and Opportunities in IBD Clinical Trial Design

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Letter: the clinical course of Crohn's disease-the Sicilian experience. Authors' reply

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. ECCO-ESGAR Topical Review on Optimizing Reporting for Cross-Sectional Imaging in Inflammatory Bowel Disease

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Praktisk anvendelse af thiopuriner hos patienter med kronisk inflammatoriske tarmsygdomme

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

Breaking through the biologic therapy efficacy plateau for inflammatory bowel disease requires the strategic development of personalized biomarkers in the tight control model. After risk stratification early in the disease course, targeted serial monitoring consistently to assess clinical outcomes in response to therapy allows for quick therapeutic adjustments before bowel damage can occur. Point-of-care intestinal ultrasound performed by the treating gastroenterologist is an accurate cross-sectional biomarker that monitors intestinal inflammation in real-time, enhances patient care, and increases shared understanding to help achieve common treatment goals. Combining intestinal ultrasound during a clinic visit with existing serum and stool biomarkers in a home testing setup with electronic health monitoring allows for an optimized, patient-centered personalized treatment algorithm that may improve treatment outcomes. Here, we review the current state, pragmatic considerations, and future implications of point-of-care testing and home testing for non-invasive inflammatory bowel disease monitoring in the tight control model.

OriginalsprogEngelsk
TidsskriftGastroenterology
Vol/bind162
Udgave nummer5
Sider (fra-til)1476-1492
Antal sider17
ISSN0016-5085
DOI
StatusUdgivet - apr. 2022

Bibliografisk note

Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

ID: 70586299